Skip to content

Author

Matthew L. Stock

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and Field Safety of the Second-Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo-Controlled Clinical Trial in Client-Owned Dogs.

BACKGROUND Janus kinase (JAK) inhibitors alleviate pruritus and clinical signs of canine atopic dermatitis (cAD). OBJECTIVE To confirm the optimal dosing regimen of atinvicitinib, a second-generation highly selective inhibitor of JAK1 in dogs. ANIMALS Sixty-one client-owned dogs, ≥ 12 months and ≥ 2 kg, with cAD....

F. Jirjis, Timothy J. Kowalski, Robin C. Lynn et al. · 0 citations
Open access Sep 2026

Gilvetmab advances immune checkpoint inhibitor immunotherapy for canine cancer.

Immune checkpoint inhibitors (ICIs) have revolutionized human oncology and are emerging as a promising strategy in veterinary cancer care. These agents unleash antitumor immunity by targeting inhibitory pathways that suppress T-cell function, enabling durable responses in select patients. In dogs, the immune checkpoint...

Esther Chon, Laura M. Greene, M. Stock · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.